ossification

SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR/RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.

LDN-212854 (BMP Inhibitor III), a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.

Secalciferol is a Vitamin D metabolite,Secalciferol is a possibly anti-inflammatory steroid which is involved in bone ossification.

Prafnosbart (DS-6016A) is a humanized monoclonal antibody that specifically targets Activin A Receptor Type 1 (ACVR1/ALK2). By binding to ACVR1, Prafnosbart blocks the binding of Activin A and the subsequent abnormal activation of downstream SMAD1/5/8 signaling pathways, thereby inhibiting the formation of heterotopic ossification (HO). Prafnosbart is primarily used to investigate bone metabolic disorders associated with ACVR1 mutations, such as Fibrodysplasia Ossificans Progressiva (FOP).

The compound AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG facilitates bone ossification and has potential applications in the study of conditions associated with osteogenic insufficiency or diminished bone mineral density (BMD), including osteoporosis [1].

Zilurgisertib fumarate (INB-000928 fumarate) is a potent and selective inhibitor of Activin Receptor-Like Kinase 2 (ALK2/ACVR1). It significantly inhibits ALK2 kinase activity (IC50 = 15 nM) and downregulates BMP-6-induced SMAD1/5 phosphorylation (IC50 = 63 nM). By blocking ALK2-mediated signaling, Zilurgisertib suppresses the production of hepcidin in hepatocytes (IC50 = 20 nM), thereby modulating iron metabolism. In preclinical studies, Zilurgisertib demonstrates the potential to improve anemia in cancer-induced models by effectively increasing hemoglobin levels.

Secalciferol (Standard) is a reference standard for research and analysis in studies involving Secalciferol. Secalciferol is a Vitamin D metabolite,Secalciferol is a possibly anti-inflammatory steroid which is involved in bone ossification.

2,3-Dimercaptopropanesulfonate (DMPS) acts as a mercury chelator. It lowers renal mercury concentrations while elevating urinary mercury levels in both uninephrectomized and normal rats treated with mercuric chloride. In a mouse model of developmental toxicity induced by heavy metals, DMPS (administered at 180 or 360 mg/kg per day for four days) mitigates methylmercury chloride-induced increases in embryotoxicity and fetal and maternal mortality, while also preventing the reduction in fetal bone ossification when given to pregnant mice.